Landauer (NYSE: LDR) and MiMedx Group (NASDAQ:MDXG) are both small-cap industrial products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares Landauer and MiMedx Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Landauer 12.09% 80.03% 10.11%
MiMedx Group 7.48% 15.95% 11.13%

Dividends

Landauer pays an annual dividend of $1.10 per share and has a dividend yield of 1.6%. MiMedx Group does not pay a dividend. Landauer pays out 57.0% of its earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of current ratings for Landauer and MiMedx Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Landauer 0 1 0 0 2.00
MiMedx Group 1 0 3 1 2.80

MiMedx Group has a consensus target price of $16.00, suggesting a potential upside of 26.68%. Given MiMedx Group’s stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Landauer.

Institutional and Insider Ownership

79.5% of Landauer shares are held by institutional investors. Comparatively, 60.4% of MiMedx Group shares are held by institutional investors. 6.6% of Landauer shares are held by insiders. Comparatively, 12.4% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Landauer has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Earnings and Valuation

This table compares Landauer and MiMedx Group’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Landauer $153.35 million 4.24 $39.95 million $1.93 34.92
MiMedx Group $283.32 million 4.78 $32.97 million $0.19 66.48

Landauer has higher revenue, but lower earnings than MiMedx Group. Landauer is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Summary

MiMedx Group beats Landauer on 10 of the 17 factors compared between the two stocks.

About Landauer

Landauer, Inc. is a provider of technical and analytical services to determine occupational and environmental radiation exposure. The Company is a provider of outsourced medical physics services, and a provider of radiology related medical products. The Company operates through three segments: Radiation Measurement, Medical Physics and Medical Products. The Company provides radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries. Medical physics services are provided through the Company’s Landauer Medical Physics (LMP) division. The Company uses LMP as a platform to expand into the medical physics services market, serving domestic hospitals, radiation therapy centers and imaging centers. The Company’s Medical Products segment provides medical consumable accessories used in radiology, radiation therapy and image guided surgery procedures.

About MiMedx Group

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Receive News & Ratings for Landauer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landauer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.